First-in-Human Trial of Photodynamic T herapy for Spinal Cord Malignant Astrocytoma: Study Protocol

다국어 초록 (Multilingual Abstract)

Our extensive basic research on photodynamic therapy (PDT) application in models of intracranial malignant astrocytoma led to its clinical application for intracranial malignant astrocytoma in Japan. Having considered the safety and effectiveness of this pathology, we initiate a first-in-human clinical study of PDT for spinal cord malignant astrocytoma. This study has an open-label, single-arm design. The initial follow-up period is 12 months, at the end of which we will quantify survival after PDT for spinal cord malignant astrocytoma as primary objective. The secondary objective is to quantify the overall progression-free survival of treated patients and the percentage of patients surviving 6 months after PDT without recurrence. Twenty patients suffering from spinal cord malignant astrocytoma will be recruited. In particular, 10 of those should be newly diagnosed World Health Organization grade 4. After obtaining consent, each patient will receive a single intravenous injection of talaporfin sodium (40 mg/m2) 1 day before tumor resection. One day after completing tumor removal, the residual lesion and/or resection cavity will be irradiated using a 664-nm semiconductor laser with a radiation power density of 150 mW/cm2 and a radiation energy density of 27 J/cm2. The procedure will be performed 22–26 hours after talaporfin sodium administration. This study protocol has been reviewed and approved by the Certified Committee in the Japanese Ministry of Health, Labor, and Welfare University Hospital Medical Information Network Clinical Trials Registry (Japan Registry of Clinical Trials number, jRCT2021220040).

참고문헌 (Reference)

1 Nayak L, "The Neurologic Assessment in Neuro-Oncology(NANO)scale : a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology(RANO)criteria" 19 : 625-635, 2017

2 Inoue T, "Shorter survival time of adolescents and young adult patients than older adults with spinal cord glioblastoma : a multicenter study" 40 : 196-205, 2023

3 Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma" 352 : 987-996, 2005

4 Adams H, "Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007" 37 : E727-E735, 2012

5 Minehan KJ, "Prognosis and treatment of spinal cord astrocytoma" 73 : 727-733, 2009

6 Akimoto J, "Photodynamic therapy for malignant brain tumors" 56 : 151-157, 2016

7 Muragaki Y, "Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors" 119 : 845-852, 2013

8 Toshiki Endo ; Tomoo Inoue ; Masaki Mizuno ; Ryu Kurokawa ; Kiyoshi Ito ; Shigeo Ueda ; Toshihiro Takami ; Kazutoshi Hida ; Minoru Hoshimaru ; Investigators of intramedullary spinal cord tumors in the Neurospinal Society of Japan, "Current trends in the surgical management of intramedullary tumors : a multicenter study of 1, 033 patients by the Neurospinal Society of Japan" 19 : 441-452, 2022

9 Chamberlain MC, "Adult primary intradural spinal cord tumors : a review" 11 : 320-328, 2011

10 Beyer S, "A systematic review on the characteristics, treatments and outcomes of the patients with primary spinal glioblastomas or gliosarcomas reported in literature until March 2015" 11 : e0148312-, 2016